SN
BMRN icon

Sittner & Nelson’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sittner & Nelson’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
2,550
-150
-6% -$8.22K 0.05% 206
2026
Q1 		$153K Hold
2,700
– – 0.06% 191
2025
Q4 		$157K Sell
2,700
-100
-4% -$5.44K 0.06% 183
2025
Q3 		$152K Sell
2,800
-300
-10% -$17.2K 0.06% 172
2025
Q2 		$170K Buy
3,100
+200
+7% +$11.8K 0.07% 155
2025
Q1 		$205K Hold
2,900
– – 0.09% 137
2024
Q4 		$191K Hold
2,900
– – 0.08% 133
2024
Q3 		$204K Sell
2,900
-100
-3% -$8.36K 0.09% 132
2024
Q2 		$247K Hold
3,000
– – 0.12% 102
2024
Q1 		$262K Buy
+3,000
New +$269K 0.13% 101
2023
Q3 		– Sell
-45
Closed -$3.9K – 468
2023
Q2 		$3.9K Buy
+45
New +$4.24K ﹤0.01% 416

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sittner & Nelson's BMRN Position: Q2 2026 in Review

Sittner & Nelson reduced its BioMarin Pharmaceuticals (BMRN) stake by 5.6% in Q2 2026, selling an estimated $8.22K and leaving 2,550 shares worth $146K. The position accounts for 0.05% of the portfolio, ranked #206.

Sittner & Nelson first reported a position in BMRN in Q2 2023 and has held it in 11 quarters since. The position peaked at $262K in Q1 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sittner & Nelson held 2,550 shares of BioMarin Pharmaceuticals worth $146K as of Q2 2026.
  • Sittner & Nelson sold 150 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.22K.
  • BioMarin Pharmaceuticals made up 0.05% of Sittner & Nelson's portfolio in Q2 2026, its #206 holding.
  • Sittner & Nelson first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Sittner & Nelson's BioMarin Pharmaceuticals position peaked at $262K in Q1 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.